Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database

• Asıl Yazarlar: Shangze Li (Yazar), Runcheng Huang (Yazar), Yuanyuan Meng (Yazar), Yijia Liu (Yazar), Jiao Qian (Yazar), Junjie Zou (Yazar), Jun Yang (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2024-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

BackgroundAssociated with enzyme deficiencies causing glycosaminoglycans (GAGs) accumulation, mucopolysaccharidosis type VI (MPS VI) is lysosomal storage disorder. In the treatment of MPS VI, galsulfase (Naglazyme) is commonly used as an enzyme replacement therapy (ERT). There remains a need for com...